SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the pricing of an underwritten

#SABS #SABSW SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/SABS/sab-bio-announ...

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants SAB Biotherapeutics (Nasdaq: SABS) commenced an underwritten public offering of common stock and, for certain investors, pre-funded warrants on March 17, 2026. The company also plans to grant underwriters a 30-day option to buy up to an additional 15% of the offered securities.Proceeds, together with existing cash and marketable securities, are intended primarily to fund continued development of SAB-142 (clinical trials, manufacturing, regulatory), and for working capital and general corporate purposes. The offering is made on a Form S-3 shelf registration declared effective January 7, 2026, and is subject to market conditions.

#SABS #SABSW SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/SABS/sab-bio-announ...

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes SAB BIO (Nasdaq: SABS) reported additional Phase 1 data for SAB-142 in adults with established type 1 diabetes showing early signals of C‑peptide preservation at Day 120 in treated participants versus placebo. The small cohort (n=6; 4 treated, 2 placebo) showed biomarker evidence of T‑cell exhaustion. SAB‑142 has advanced to the registrational Phase 2b SAFEGUARD trial with topline data expected 2H 2027.

#SABS #SABSW SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

www.stocktitan.net/news/SABS/sab-bio-announ...

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027 Reported Phase 1 clinical data, including healthy volunteer, redosing, and T1D cohorts supporting

#SABS #SABSW SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

www.stocktitan.net/news/SABS/sab-bio-report...

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D SAB BIO (Nasdaq: SABS) announced positive confirmatory Phase 1 results for SAB-142, an hATG candidate for stage 3 type 1 diabetes (T1D). In 68 treated participants (healthy volunteers and T1D patients), SAB-142 showed 0% serum sickness (0/68), 0% anti-drug antibody events (0/68), no drug-related serious adverse events, and transient lymphopenia that resolved to baseline within 1–3 days in 100% of subjects (68/68). Most adverse events were mild and infusion-related. A registrational Phase 2b SAFEGUARD trial is underway and recruiting globally, with the company on track to dose the first patient by year-end.

#SABS #SABSW SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

www.stocktitan.net/news/SABS/sab-bio-announ...

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights SAB BIO (Nasdaq: SABS) initiated its registrational Phase 2b SAFEGUARD trial of lead candidate SAB-142 in new-onset Stage 3 T1D, activated multiple sites in the US, Australia and New Zealand, and is on-track to dose the first patient by year-end 2025. The company reported a strong cash position of $161.5 million at Sept 30, 2025 (vs. $20.8 million at Dec 31, 2024) and said its runway extends through 2028. Phase 1 data presented at EASD and ISPAD showed a favorable safety profile, no serum sickness or anti-drug antibodies at the target dose, and sustained immunomodulation. Financials: Q3 R&D $9.0M, other income $58.1M, and Q3 net income $45.4M. Company expects SAFEGUARD data in 2H 2027 and to present additional Phase 1 redosing data by year-end 2025.

#SABS #SABSW SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

www.stocktitan.net/news/SABS/sab-bio-report...

Breakthrough in Type 1 Diabetes: SAB BIO's SAB-142 Shows Sustained Effects Without Lymphodepletion in Phase 1 SAB BIO presents Phase 1 data for SAB-142 in T1D showing sustained immunomodulation without lymphodepletion. Study included 68 subjects, with effects lasting 120 days. Phase 2b SAFEGUARD study now initiated.

#SABS #SABSW SAB BIO Highlights Data in Multiple Presentations at EASD

www.stocktitan.net/news/SABS/sab-bio-highli...

Breakthrough Type 1 Diabetes Treatment: SAB BIO to Showcase Novel Immunotherapy SAB-142 in 5 EASD Sessions SAB Biotherapeutics will deliver 4 oral presentations and symposium on SAB-142, a human anti-thymocyte immunoglobulin for type 1 diabetes, at EASD 2025 in Vienna, September 15-19.

#SABS #SABSW SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

www.stocktitan.net/news/SABS/sab-bio-to-del...

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates SAB BIO (Nasdaq: SABS) has announced significant developments in Q2 2025, highlighted by a $175 million oversubscribed private placement that included strategic investor Sanofi. The financing extends the company's operational runway until mid-2028 and will fully fund their pivotal Phase 2b SAFEGUARD study for SAB-142, their lead candidate for delaying type 1 diabetes progression.The company achieved FDA alignment on the SAFEGUARD study design, scheduled to begin in Q3 2025. The private placement included issuing 1 million shares of Series B preferred stock at $1.75 per share conversion price, plus warrants for potential additional proceeds of $284 million.Financial results showed cash position of $5.7 million as of June 30, 2025, with Q2 R&D expenses at $7.0 million and a net loss of $10.1 million.

#SABS #SABSW SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

www.stocktitan.net/news/SABS/sab-bio-report...

SAB BIO Announces Oversubscribed $175 Million Private Placement SAB BIO (Nasdaq: SABS) has secured a significant $175 million private placement with participation from strategic investor Sanofi and several prominent institutional investors. The oversubscribed financing includes the issuance of 1,000,000 shares of Series B nonvoting convertible preferred stock at a conversion price of $1.75 per share.The company will also issue warrants that could provide up to an additional $284 million in gross proceeds if exercised in full. The proceeds will fund the pivotal Phase 2b SAFEGUARD study of SAB-142 for delaying progression of autoimmune Type 1 Diabetes (T1D) in newly diagnosed patients, extending the company's cash runway into mid-2028.

#SABS #SABSW SAB BIO Announces Oversubscribed $175 Million Private Placement

www.stocktitan.net/news/SABS/sab-bio-announ...

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates SAB BIO (NASDAQ: SABS) has reported its Q1 2025 financial results and company updates. The clinical-stage biopharmaceutical company completed patient dosing in the last cohort of the Phase 1 clinical study of SAB-142, their novel immunotherapy for delaying type 1 diabetes progression. The company reported cash and equivalents of $12.9 million, down from $20.8 million in December 2024.Financial highlights include R&D expenses of $7.7 million (down from $8.1 million YoY), reduced G&A expenses of $3.1 million (down from $4.2 million YoY), and other income of $5.6 million. The company reported a net loss of $5.2 million. SAB BIO also achieved a significant milestone by obtaining a Qualified Person declaration for their in-house CMC manufacturing process, enabling them to meet European manufacturing standards for upcoming EU clinical trials.

#SABS #SABSW SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

www.stocktitan.net/news/SABS/sab-bio-announ...

SAB Bio's Diabetes Breakthrough: Phase 1 Success Drives Path to Phase 2b Trials Type 1 Diabetes therapy SAB-142 achieves safety and efficacy goals in Phase 1, advancing to Phase 2b amid improved annual losses. See full clinical and financial details.

#SABS #SABSW SAB BIO Reports Full Year 2024 Operating and Financial Results

www.stocktitan.net/news/SABS/sab-bio-report...

Revolutionary Type 1 Diabetes Drug Aces Safety Tests, Outpatient Treatment Now Possible SAB BIO's SAB-142 achieves key trial milestones for type 1 diabetes treatment, demonstrating exceptional safety and sustained immunomodulation. Phase 2b trials planned for 2025.

#SABS #SABSW SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

www.stocktitan.net/news/SABS/sab-bio-announ...

SAB BIO to Present Phase 1 Type 1 Diabetes Treatment Data in Upcoming R&D Webinar SAB BIO announces R&D webinar featuring Phase 1 trial results for SAB-142, a novel immunotherapy treatment for type 1 diabetes, with expert Dr. Michael Haller on January 28.

#SABS #SABSW SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

www.stocktitan.net/news/SABS/sab-bio-announ...